2021 Canadian Thoracic Society Guideline – A focused update on the management of very mild and mild asthma, Connie L. Yang, Elizabeth Anne Hicks, Patrick Mitchell, Joe Reisman, Delanya Podgers, Kathleen M. Hayward, Mark Waite & Clare D. Ramsey Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 5:4, 205-245, DOI: 10.1080/24745332.2021.1877043
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, Buhl R, Cruz AA, Fleming L, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Pedersen SE, Sheikh A, Yorgancioglu A, Boulet LP. Eur Respir J. 2019 Jun 27;53(6). pii: 1901046. doi: 10.1183/13993003.01046-2019. Print 2019 Jun. PMID: 31249014
CONCLUSIONS: In patients with mild asthma, as-needed budesonide-formoterol provided superior asthma-symptom control to as-needed terbutaline, assessed according to electronically recorded weeks with well-controlled asthma, but was inferior to budesonide maintenance therapy. Exacerbation rates with the two budesonide-containing regimens were similar and were lower than the rate with terbutaline. Budesonide-formoterol used as needed resulted in substantially lower glucocorticoid exposure than budesonide maintenance therapy.